Baculovirus Expression Vector Systems (BEVs) refers generally to a family of integrated and patented technologies that use genetically engineered baculovirus genomes called baculovirus expression vectors (BEVs) and their host cells to express heterologous proteins. There are a number of general benefits of this technology, but meaningful assessment of the utility of baculovirus expression for a specific protein in comparison to other expression technologies requires an understanding and appreciation of specific approaches and strategies contemplated to be used, because the features, benefits and limitations of these systems are dependent upon the specific technologies employed. For instance, the promoter elements of BEVs can determine whether the expression system is transient-lethal or recombinant-stable. This has very significant impact upon scale-up, regulatory requirements and process development. Signal sequences within the BEV can affect the efficiency of product expression. The efficiency of introduction of heterologous sequences into BEVs is greatly affected by the nature of the transfer vector used. Various techniques are controlled by patents that may affect commercial freedom to operate (FTO) and profit potential.
Specialties
Media products manufactured with
components certified to be animal origin free
Media manufactured in cGMP facilities
Performance tested for growth and productivity
Advantages
No animal components to impact down-stream purification